trial

The Optimal Treatment for Treatment-resistant Schizophrenia

NCTId NCT02926976
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 150 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2019-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-11
Primary completion
2019-09
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
RisperidoneAripiprazoleClozapine

Sponsors

Shanghai Mental Health CenterLead Sponsor

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
150
Phase
NA
Primary Completion Date
2019-09
Status
UNKNOWN
relationships
The graph out of here
drug
Risperidone
drug
Aripiprazole
drug
Clozapine
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication